NDC 83634-115-41 - Vancomycin Hydrochloride
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 83634-115
- Requested NDC
- 83634-115-41
- Package NDCs from labels
- 83634-115-41, 83634-115-30
- Manufacturer
- Avenacy, LLC
- Effective date
- 2026-07-31
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Vancomycin Hydrochloride - Avenacy, LLC | Avenacy, LLC | 2026-07-31 | HUMAN PRESCRIPTION DRUG LABEL |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Meitheal Pharmaceuticals Inc. | 45642a47-4712-4a12-8cf7-ee6c2ab8e6c6 | 2023-09-29 | Warnings, Adverse reactions | 71WO621TJD |
| VANCOMYCIN HYDROCHLORIDE | VANCOMYCIN HYDROCHLORIDE | Fresenius Kabi USA, LLC | 0576803d-95de-4a48-806a-69ae3fcaf6b0 | 2023-08-17 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin hydrochloride | VANCOMYCIN HYDROCHLORIDE | Eugia US LLC | 9aa42538-c84e-4886-8d3d-a7dfded5120f | 2023-08-05 | Warnings, Adverse reactions | 2049890 2049888 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Gland Pharma Limited | 35ecffbc-77d8-4c0d-9b14-6a3cc442dec6 | 2023-07-13 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Amneal Pharmaceuticals NY LLC | 3c47d5c4-8cdb-4701-8d7a-8a6e79025b53 | 2023-06-23 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin hydrochloride | VANCOMYCIN HYDROCHLORIDE | Meitheal Pharmaceuticals Inc. | e5e26614-4119-40cc-b092-48ab97a41287 | 2023-03-27 | Warnings, Adverse reactions | 1807518 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Fresenius Kabi USA, LLC | 0713a847-a334-4b73-af22-343aa06621b9 | 2023-02-07 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Fresenius Kabi, LLC | 8a35ebee-8650-4ef5-84f5-ab9b55d9bc19 | 2022-12-02 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Fresenius Kabi, LLC | 418c3c6a-d08d-448c-89c9-54e558c1ce16 | 2022-12-02 | Warnings, Adverse reactions | 71WO621TJD |
| Refresh Digital PF | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN AND POLYSORBATE 80 | Allergan, Inc. | 97e83e68-6374-4df4-93f6-d707fc32748d | 2022-11-28 | Warnings | 6OZP39ZG8H |
| Refresh Digital | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, POLYSORBATE 80 | Allergan, Inc. | b2bd34d4-fab9-4f4b-9be2-5d30b55f5b81 | 2022-11-28 | Warnings | 6OZP39ZG8H |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | BluePoint Laboratories | f28e3c2b-ae31-4c2a-8178-53962b7b213c | 2022-09-22 | Warnings, Adverse reactions | 71WO621TJD |
| REFRESH OPTIVE Advanced | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, POLYSORBATE 80 | Allergan, Inc. | ebd0839e-2e1d-4e0e-986c-19f1f5c76358 | 2022-09-19 | Warnings | 6OZP39ZG8H |
| REFRESH OPTIVE Advanced | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, AND POLYSORBATE 80 | Allergan, Inc. | aaa943e4-7c38-4c5a-b7c0-5a656d8cafc0 | 2022-09-01 | Warnings | 6OZP39ZG8H |
| VANCOMYCIN HYDROCHLORIDE | VANCOMYCIN HYDROCHLORIDE | Camber Pharmaceuticals, Inc. | 3f5dacea-af40-4103-b128-c5e0c0c52fa1 | 2022-07-20 | Warnings, Adverse reactions | 71WO621TJD |
| REFRESH Optive Mega-3 | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN AND POLYSORBATE 80 | Allergan, Inc. | c5f2b3f2-2071-45bd-a010-67f848bc0233 | 2022-06-30 | Warnings | 6OZP39ZG8H |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Hikma Pharmaceuticals USA Inc. | 86950e7c-0114-47e9-8891-e09e595c48c3 | 2022-02-25 | Warnings, Adverse reactions | 1807518 |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Hikma Pharmaceuticals USA Inc. | cae9e5f3-b89a-4a7f-93f7-9471c74a3559 | 2021-12-07 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Fresenius Kabi USA, LLC | d3147f2d-1a72-4923-874b-8fdee2be625e | 2021-09-30 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Mylan Institutional LLC | ce139a51-0471-4c31-b456-2f889f18dd2b | 2021-09-15 | Warnings, Adverse reactions | 71WO621TJD |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.